Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

New drug effectively decreases recurrence of and death from endometrial cancer (opens in a new tab)

news-medical.net · 2026-10-26

Short answerEvidenceSource

Short answer

Not assessed

Check incomplete.

We found a likely source study, but its evidence could not be prepared for claim review. The article's claims remain unverified.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Source study identified.

A source study was identified, but the study's evidence could not be prepared for claim assessment. No claim verdicts are available.

View article claims
3

The source study

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial

The Lancet · 2026
Open source record (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

A source study was identified, but the study's evidence could not be prepared for claim assessment. The claims below have not been assessed.

Claim 1 of 6Not checkedA new drug, sacituzumab tirumotecan (sac-TMT), is effective at decreasing recurrence of and death from endometrial cancer, according to a landmark international study.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 2 of 6Not checkedThe study compared sac-TMT with standard chemotherapy in women who had already been treated with chemotherapy and then immunotherapy for advanced or recurring endometrial cancer.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 3 of 6Not checkedIn the phase 3 trial, 386 women assigned to sac-TMT had a 41 percent lower risk of progression than 390 women treated with chemotherapy alone after immunotherapy, and the risk of death was 32 percent lower.View evidenceHide evidence

As stated41 percent lower risk of progression; 32 percent lower risk of death

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 4 of 6Not checkedMore women treated with sac-TMT responded to treatment than those given standard chemotherapy, with response rates of 35.1 percent versus 17.3 percent.View evidenceHide evidence

As stated35.1 percent versus 17.3 percent

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 5 of 6Not checkedThe most frequent side effects in the sac-TMT group were low blood counts, mouth inflammation, and dry or itchy eyes, which the researchers said were manageable.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Claim 6 of 6Not checkedStudy investigators said the results support sac-TMT as a new standard treatment in recurrent endometrial cancer and may prompt guideline reassessment.View evidenceHide evidence

Not checked

A source study was identified, but the evidence comparison for this claim was not completed. No verdict has been assigned.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial

The Lancet · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 39 candidate papers

Selected

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial

The Lancet · 2026 · Crossref

Source (opens in a new tab)
Candidate

Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

The Lancet. Oncology · 2026 · PubMed, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)

And 33 more candidates considered.